Overview

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment of subjects with Her2-negative metastatic or locally recurrent breast cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Paclitaxel
Trebananib